| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Chikungunya Fever | 13 | 2019 | 345 | 5.63 | Why? |
| Zika Virus Infection | 25 | 2020 | 1920 | 5.46 | Why? |
| Colombia | 36 | 2021 | 1241 | 4.20 | Why? |
| Travel Medicine | 10 | 2020 | 335 | 2.63 | Why? |
| Zika Virus | 15 | 2020 | 1924 | 2.22 | Why? |
| Giardiasis | 5 | 2018 | 34 | 1.94 | Why? |
| Latin America | 16 | 2021 | 1721 | 1.87 | Why? |
| Bibliometrics | 6 | 2020 | 731 | 1.79 | Why? |
| Zoonoses | 9 | 2020 | 3034 | 1.72 | Why? |
| Chikungunya virus | 6 | 2019 | 339 | 1.67 | Why? |
| Coinfection | 10 | 2021 | 6820 | 1.64 | Why? |
| Tropical Climate | 3 | 2021 | 179 | 1.46 | Why? |
| Dengue | 9 | 2021 | 1565 | 1.46 | Why? |
| Giardia lamblia | 2 | 2017 | 20 | 1.44 | Why? |
| Disease Reservoirs | 7 | 2021 | 1672 | 1.33 | Why? |
| Chiroptera | 6 | 2021 | 3530 | 1.31 | Why? |
| Travel | 12 | 2020 | 7220 | 1.26 | Why? |
| Geographic Information Systems | 6 | 2020 | 507 | 1.23 | Why? |
| Coronavirus Infections | 56 | 2021 | 253789 | 1.23 | Why? |
| Communicable Diseases, Emerging | 6 | 2020 | 2523 | 1.16 | Why? |
| Pneumonia, Viral | 52 | 2021 | 243684 | 1.15 | Why? |
| Mosquito Control | 2 | 2017 | 237 | 1.14 | Why? |
| Aedes | 2 | 2018 | 380 | 1.10 | Why? |
| Peru | 9 | 2021 | 1010 | 1.08 | Why? |
| Bolivia | 6 | 2020 | 187 | 1.03 | Why? |
| Helminthiasis | 2 | 2021 | 78 | 1.03 | Why? |
| Cat Diseases | 2 | 2020 | 539 | 0.97 | Why? |
| Venezuela | 6 | 2020 | 172 | 0.97 | Why? |
| Transients and Migrants | 3 | 2020 | 1468 | 0.94 | Why? |
| Microcephaly | 3 | 2018 | 181 | 0.94 | Why? |
| Betacoronavirus | 48 | 2020 | 204454 | 0.93 | Why? |
| Humans | 173 | 2021 | 930598 | 0.93 | Why? |
| Tuberculosis | 4 | 2021 | 2895 | 0.91 | Why? |
| Pandemics | 60 | 2021 | 389249 | 0.87 | Why? |
| Helminths | 1 | 2021 | 60 | 0.86 | Why? |
| Pregnancy Complications, Infectious | 11 | 2020 | 11559 | 0.86 | Why? |
| Felidae | 1 | 2020 | 23 | 0.85 | Why? |
| Antiprotozoal Agents | 2 | 2019 | 83 | 0.85 | Why? |
| Diphtheria | 1 | 2020 | 74 | 0.82 | Why? |
| SARS Virus | 6 | 2020 | 13021 | 0.82 | Why? |
| Severe Acute Respiratory Syndrome | 6 | 2020 | 12361 | 0.81 | Why? |
| Catholicism | 1 | 2020 | 64 | 0.80 | Why? |
| Refugees | 3 | 2019 | 809 | 0.80 | Why? |
| El Nino-Southern Oscillation | 1 | 2018 | 7 | 0.79 | Why? |
| Ceremonial Behavior | 1 | 2020 | 63 | 0.78 | Why? |
| Clarithromycin | 1 | 2020 | 112 | 0.78 | Why? |
| Memory, Short-Term | 1 | 2020 | 137 | 0.78 | Why? |
| Human Development | 1 | 2018 | 7 | 0.77 | Why? |
| Disease Outbreaks | 14 | 2021 | 27595 | 0.75 | Why? |
| Taeniasis | 1 | 2017 | 9 | 0.74 | Why? |
| Malaria | 2 | 2019 | 1097 | 0.74 | Why? |
| Bartonella Infections | 1 | 2018 | 18 | 0.73 | Why? |
| Arenavirus | 1 | 2018 | 51 | 0.73 | Why? |
| Ecosystem | 2 | 2021 | 776 | 0.72 | Why? |
| Insect Vectors | 2 | 2017 | 227 | 0.72 | Why? |
| Aneurysm, Infected | 1 | 2018 | 36 | 0.72 | Why? |
| Kyasanur Forest Disease | 1 | 2017 | 9 | 0.72 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 4 | 2021 | 8843 | 0.71 | Why? |
| Urinary Bladder | 1 | 2019 | 170 | 0.71 | Why? |
| Leishmaniasis, Visceral | 1 | 2019 | 85 | 0.71 | Why? |
| Paragonimiasis | 1 | 2017 | 6 | 0.71 | Why? |
| Pest Control, Biological | 1 | 2017 | 11 | 0.71 | Why? |
| Toxoplasmosis, Cerebral | 1 | 2017 | 12 | 0.70 | Why? |
| Meningitis, Haemophilus | 1 | 2017 | 12 | 0.70 | Why? |
| Encephalitis Virus, St. Louis | 1 | 2017 | 3 | 0.70 | Why? |
| Encephalitis, St. Louis | 1 | 2017 | 3 | 0.70 | Why? |
| Parasitology | 1 | 2017 | 17 | 0.70 | Why? |
| Toxoplasmosis, Congenital | 1 | 2017 | 10 | 0.70 | Why? |
| Hematocrit | 1 | 2017 | 107 | 0.69 | Why? |
| Cysticercosis | 1 | 2017 | 32 | 0.69 | Why? |
| Encephalomyelitis, Venezuelan Equine | 1 | 2017 | 16 | 0.69 | Why? |
| Human Migration | 1 | 2019 | 133 | 0.69 | Why? |
| Drug Resistance, Multiple, Fungal | 1 | 2017 | 45 | 0.67 | Why? |
| Meningitis, Aseptic | 1 | 2017 | 22 | 0.67 | Why? |
| Leishmaniasis, Cutaneous | 1 | 2017 | 48 | 0.67 | Why? |
| Histamine Antagonists | 1 | 2018 | 203 | 0.67 | Why? |
| Cyclonic Storms | 1 | 2021 | 236 | 0.67 | Why? |
| Lassa Fever | 1 | 2018 | 88 | 0.66 | Why? |
| Phlebovirus | 1 | 2018 | 106 | 0.66 | Why? |
| Crowding | 2 | 2020 | 731 | 0.66 | Why? |
| Flavivirus | 2 | 2017 | 182 | 0.66 | Why? |
| Immunotherapy | 2 | 2020 | 2421 | 0.65 | Why? |
| Fetal Growth Retardation | 1 | 2019 | 217 | 0.65 | Why? |
| Bunyaviridae Infections | 1 | 2018 | 107 | 0.65 | Why? |
| Alphavirus | 1 | 2017 | 90 | 0.65 | Why? |
| Neglected Diseases | 2 | 2018 | 381 | 0.65 | Why? |
| Haemophilus influenzae | 1 | 2017 | 196 | 0.63 | Why? |
| Candidiasis, Invasive | 1 | 2017 | 107 | 0.62 | Why? |
| Gastroenterologists | 1 | 2020 | 259 | 0.62 | Why? |
| Acquired Immunodeficiency Syndrome | 2 | 2020 | 533 | 0.62 | Why? |
| Animals, Wild | 2 | 2021 | 1028 | 0.61 | Why? |
| Arthritis, Infectious | 1 | 2017 | 111 | 0.61 | Why? |
| Coronavirus | 9 | 2020 | 18339 | 0.61 | Why? |
| Alopecia | 1 | 2021 | 351 | 0.61 | Why? |
| Incidence | 15 | 2021 | 25622 | 0.61 | Why? |
| Honduras | 3 | 2021 | 117 | 0.61 | Why? |
| Serum | 1 | 2017 | 294 | 0.60 | Why? |
| Tuberculosis, Meningeal | 1 | 2017 | 100 | 0.60 | Why? |
| One Health | 1 | 2020 | 390 | 0.59 | Why? |
| Central America | 3 | 2020 | 86 | 0.59 | Why? |
| Hemoptysis | 1 | 2018 | 172 | 0.58 | Why? |
| Flavivirus Infections | 1 | 2015 | 81 | 0.57 | Why? |
| HIV | 2 | 2019 | 1116 | 0.56 | Why? |
| Pericarditis | 1 | 2020 | 417 | 0.56 | Why? |
| Camelus | 2 | 2020 | 1425 | 0.56 | Why? |
| Embolization, Therapeutic | 1 | 2018 | 269 | 0.55 | Why? |
| Arthritis | 1 | 2018 | 288 | 0.55 | Why? |
| Public Health | 8 | 2021 | 16359 | 0.54 | Why? |
| Molecular Epidemiology | 1 | 2020 | 1638 | 0.53 | Why? |
| Disease Notification | 1 | 2020 | 639 | 0.53 | Why? |
| Vaccines | 3 | 2021 | 3692 | 0.52 | Why? |
| Animals | 27 | 2021 | 78931 | 0.51 | Why? |
| Emigration and Immigration | 1 | 2019 | 501 | 0.51 | Why? |
| Fetus | 1 | 2017 | 484 | 0.51 | Why? |
| Epidemics | 7 | 2020 | 6407 | 0.50 | Why? |
| Spatio-Temporal Analysis | 1 | 2019 | 1182 | 0.50 | Why? |
| Candida | 1 | 2017 | 425 | 0.49 | Why? |
| Sports | 2 | 2020 | 690 | 0.49 | Why? |
| Biological Therapy | 1 | 2016 | 456 | 0.47 | Why? |
| Mucormycosis | 1 | 2021 | 832 | 0.46 | Why? |
| Interleukin-8 | 1 | 2017 | 964 | 0.44 | Why? |
| Coronavirus 229E, Human | 1 | 2020 | 1241 | 0.44 | Why? |
| Vaccination Coverage | 1 | 2020 | 1249 | 0.44 | Why? |
| Orthomyxoviridae | 1 | 2020 | 1168 | 0.44 | Why? |
| Sexually Transmitted Diseases | 2 | 2018 | 694 | 0.43 | Why? |
| Global Health | 9 | 2020 | 13911 | 0.43 | Why? |
| Air Microbiology | 1 | 2021 | 1322 | 0.43 | Why? |
| Publishing | 2 | 2018 | 990 | 0.43 | Why? |
| Tuberculosis, Pulmonary | 2 | 2018 | 1171 | 0.42 | Why? |
| Mass Vaccination | 1 | 2021 | 1101 | 0.42 | Why? |
| Surgery Department, Hospital | 1 | 2020 | 954 | 0.42 | Why? |
| Climate Change | 1 | 2018 | 901 | 0.41 | Why? |
| Military Personnel | 1 | 2020 | 1097 | 0.41 | Why? |
| Simulation Training | 1 | 2020 | 957 | 0.41 | Why? |
| Preventive Health Services | 1 | 2016 | 501 | 0.41 | Why? |
| Guidelines as Topic | 2 | 2020 | 2844 | 0.40 | Why? |
| Health Personnel | 5 | 2020 | 29646 | 0.40 | Why? |
| Cats | 4 | 2020 | 1890 | 0.40 | Why? |
| Health Knowledge, Attitudes, Practice | 5 | 2020 | 8811 | 0.40 | Why? |
| Dengue Virus | 3 | 2021 | 910 | 0.39 | Why? |
| Semen | 1 | 2015 | 550 | 0.39 | Why? |
| Nepal | 4 | 2021 | 1004 | 0.39 | Why? |
| Animals, Domestic | 2 | 2021 | 272 | 0.38 | Why? |
| Kidney | 3 | 2020 | 3648 | 0.37 | Why? |
| Epidemiological Monitoring | 3 | 2020 | 3493 | 0.37 | Why? |
| Vaccination | 8 | 2021 | 19050 | 0.36 | Why? |
| Plasmodium vivax | 2 | 2019 | 154 | 0.36 | Why? |
| Community-Acquired Infections | 1 | 2021 | 2328 | 0.36 | Why? |
| Immunization Programs | 1 | 2021 | 2006 | 0.35 | Why? |
| Premature Birth | 1 | 2020 | 2151 | 0.35 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2019 | 1380 | 0.34 | Why? |
| Immunomodulation | 1 | 2016 | 1472 | 0.34 | Why? |
| Mycobacterium tuberculosis | 1 | 2017 | 1164 | 0.34 | Why? |
| Intensive Care Units | 5 | 2020 | 29594 | 0.34 | Why? |
| Research | 2 | 2017 | 2115 | 0.34 | Why? |
| Viruses | 1 | 2021 | 2238 | 0.34 | Why? |
| Immunity, Cellular | 1 | 2020 | 3614 | 0.34 | Why? |
| South America | 3 | 2020 | 565 | 0.33 | Why? |
| Guillain-Barre Syndrome | 2 | 2017 | 1495 | 0.33 | Why? |
| Developing Countries | 3 | 2018 | 4283 | 0.33 | Why? |
| Brazil | 7 | 2021 | 12582 | 0.32 | Why? |
| Urban Population | 1 | 2017 | 2000 | 0.32 | Why? |
| Americas | 2 | 2018 | 418 | 0.32 | Why? |
| Taiwan | 3 | 2020 | 2556 | 0.31 | Why? |
| Arbovirus Infections | 2 | 2018 | 104 | 0.31 | Why? |
| Social Determinants of Health | 1 | 2018 | 1757 | 0.31 | Why? |
| Socioeconomic Factors | 3 | 2021 | 8495 | 0.31 | Why? |
| Geography, Medical | 2 | 2020 | 537 | 0.30 | Why? |
| Health Communication | 1 | 2017 | 1120 | 0.30 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2021 | 13720 | 0.30 | Why? |
| HIV Infections | 3 | 2021 | 11620 | 0.30 | Why? |
| Milk, Human | 3 | 2020 | 956 | 0.30 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.28 | Why? |
| Rheumatic Diseases | 2 | 2018 | 2675 | 0.28 | Why? |
| Olfaction Disorders | 2 | 2020 | 3704 | 0.28 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.28 | Why? |
| Viral Vaccines | 3 | 2020 | 7560 | 0.28 | Why? |
| Meningoencephalitis | 2 | 2018 | 208 | 0.28 | Why? |
| Rural Population | 1 | 2017 | 2408 | 0.27 | Why? |
| Prevalence | 8 | 2021 | 25773 | 0.27 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.27 | Why? |
| Surgical Procedures, Operative | 1 | 2020 | 2662 | 0.27 | Why? |
| Adult | 27 | 2021 | 244371 | 0.27 | Why? |
| Endemic Diseases | 2 | 2019 | 480 | 0.27 | Why? |
| Geography | 2 | 2021 | 1801 | 0.27 | Why? |
| Pregnancy | 9 | 2020 | 23879 | 0.26 | Why? |
| Animals, Zoo | 2 | 2021 | 106 | 0.26 | Why? |
| Delivery of Health Care | 5 | 2020 | 15909 | 0.25 | Why? |
| Sex Distribution | 2 | 2021 | 2083 | 0.25 | Why? |
| Female | 35 | 2021 | 380317 | 0.25 | Why? |
| Male | 31 | 2021 | 367725 | 0.25 | Why? |
| Autoimmune Diseases | 1 | 2016 | 1996 | 0.25 | Why? |
| Infant, Newborn | 6 | 2021 | 23105 | 0.25 | Why? |
| Depression | 2 | 2017 | 14116 | 0.25 | Why? |
| Asymptomatic Infections | 2 | 2021 | 7218 | 0.24 | Why? |
| Disease Transmission, Infectious | 4 | 2020 | 9044 | 0.24 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.23 | Why? |
| Lipoxygenase Inhibitors | 1 | 2021 | 18 | 0.23 | Why? |
| Regression Analysis | 2 | 2020 | 2484 | 0.23 | Why? |
| Primary Health Care | 1 | 2020 | 4839 | 0.23 | Why? |
| Muscle Hypotonia | 1 | 2021 | 16 | 0.23 | Why? |
| Communicable Diseases, Imported | 2 | 2020 | 843 | 0.23 | Why? |
| Arachidonate 5-Lipoxygenase | 1 | 2021 | 51 | 0.22 | Why? |
| Young Adult | 14 | 2021 | 93724 | 0.22 | Why? |
| Snakes | 1 | 2020 | 53 | 0.22 | Why? |
| Tigers | 1 | 2020 | 43 | 0.22 | Why? |
| West Indies | 1 | 2020 | 48 | 0.22 | Why? |
| Cross-Sectional Studies | 10 | 2021 | 53120 | 0.22 | Why? |
| Confidence Intervals | 2 | 2021 | 744 | 0.22 | Why? |
| Infectious Disease Transmission, Vertical | 4 | 2020 | 5164 | 0.22 | Why? |
| Education, Medical | 1 | 2018 | 2461 | 0.22 | Why? |
| Melia azedarach | 1 | 2020 | 11 | 0.21 | Why? |
| Th2 Cells | 2 | 2021 | 680 | 0.21 | Why? |
| Task Performance and Analysis | 1 | 2020 | 68 | 0.21 | Why? |
| Stress Disorders, Post-Traumatic | 1 | 2017 | 2963 | 0.21 | Why? |
| Viverridae | 1 | 2020 | 225 | 0.21 | Why? |
| Asia | 2 | 2018 | 2399 | 0.21 | Why? |
| Pentamidine | 1 | 2019 | 3 | 0.20 | Why? |
| Arthralgia | 2 | 2018 | 173 | 0.20 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.20 | Why? |
| Sneezing | 1 | 2021 | 173 | 0.20 | Why? |
| Maps as Topic | 1 | 2019 | 24 | 0.20 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.20 | Why? |
| Primaquine | 1 | 2019 | 62 | 0.20 | Why? |
| Phosphorylcholine | 1 | 2019 | 15 | 0.20 | Why? |
| Dissection | 1 | 2021 | 164 | 0.20 | Why? |
| Cough | 4 | 2021 | 4891 | 0.19 | Why? |
| Alice in Wonderland Syndrome | 1 | 2018 | 2 | 0.19 | Why? |
| Rodent Diseases | 1 | 2020 | 115 | 0.19 | Why? |
| Primate Diseases | 1 | 2020 | 110 | 0.19 | Why? |
| Genome, Viral | 3 | 2020 | 13157 | 0.19 | Why? |
| Gene-Environment Interaction | 1 | 2020 | 127 | 0.19 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.19 | Why? |
| Population | 1 | 2019 | 114 | 0.19 | Why? |
| Cross Infection | 2 | 2021 | 8675 | 0.19 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.19 | Why? |
| Gloves, Protective | 1 | 2020 | 249 | 0.18 | Why? |
| Eutheria | 1 | 2020 | 313 | 0.18 | Why? |
| Blood Vessels | 1 | 2020 | 228 | 0.18 | Why? |
| Sexually Transmitted Diseases, Viral | 1 | 2020 | 115 | 0.18 | Why? |
| Rodentia | 1 | 2020 | 235 | 0.18 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.18 | Why? |
| Synovial Fluid | 1 | 2018 | 64 | 0.18 | Why? |
| Caribbean Region | 4 | 2021 | 349 | 0.18 | Why? |
| Diagnosis, Differential | 3 | 2017 | 7220 | 0.18 | Why? |
| Malaria, Vivax | 1 | 2019 | 152 | 0.18 | Why? |
| Wolbachia | 1 | 2017 | 9 | 0.18 | Why? |
| Infection Control | 4 | 2020 | 23131 | 0.18 | Why? |
| Quinacrine | 1 | 2017 | 35 | 0.17 | Why? |
| Toxoplasmosis | 1 | 2018 | 59 | 0.17 | Why? |
| Rain | 1 | 2018 | 108 | 0.17 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.17 | Why? |
| RNA, Viral | 5 | 2021 | 32276 | 0.17 | Why? |
| Arboviruses | 1 | 2018 | 76 | 0.17 | Why? |
| Physicians | 1 | 2017 | 4214 | 0.17 | Why? |
| Nitroimidazoles | 1 | 2017 | 69 | 0.17 | Why? |
| Mammals | 1 | 2020 | 315 | 0.17 | Why? |
| Tokyo | 1 | 2020 | 645 | 0.17 | Why? |
| Sexual Behavior | 2 | 2017 | 1322 | 0.17 | Why? |
| Models, Animal | 1 | 2020 | 788 | 0.17 | Why? |
| Ocular Motility Disorders | 1 | 2017 | 55 | 0.17 | Why? |
| Spermatozoa | 1 | 2020 | 244 | 0.17 | Why? |
| Phylogeny | 4 | 2021 | 13341 | 0.17 | Why? |
| Acetaminophen | 1 | 2020 | 326 | 0.17 | Why? |
| Eye Protective Devices | 1 | 2020 | 245 | 0.17 | Why? |
| Students, Health Occupations | 1 | 2020 | 224 | 0.17 | Why? |
| Iran | 2 | 2020 | 5467 | 0.17 | Why? |
| Economics | 1 | 2019 | 196 | 0.17 | Why? |
| Larva | 1 | 2017 | 153 | 0.17 | Why? |
| Primates | 1 | 2020 | 584 | 0.17 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.16 | Why? |
| Animals, Genetically Modified | 1 | 2017 | 230 | 0.16 | Why? |
| Ecuador | 1 | 2019 | 514 | 0.16 | Why? |
| Ataxia | 1 | 2017 | 133 | 0.16 | Why? |
| Tick-Borne Diseases | 1 | 2017 | 68 | 0.16 | Why? |
| Culex | 1 | 2017 | 66 | 0.16 | Why? |
| Rubella | 1 | 2018 | 127 | 0.16 | Why? |
| World Health Organization | 2 | 2020 | 4213 | 0.16 | Why? |
| Indonesia | 2 | 2019 | 1022 | 0.16 | Why? |
| Angiography | 1 | 2018 | 301 | 0.16 | Why? |
| Protective Clothing | 1 | 2020 | 468 | 0.16 | Why? |
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2019 | 198 | 0.16 | Why? |
| Databases, Bibliographic | 1 | 2017 | 182 | 0.16 | Why? |
| Meningitis, Cryptococcal | 1 | 2017 | 79 | 0.16 | Why? |
| Fever | 4 | 2021 | 7795 | 0.16 | Why? |
| Dogs | 2 | 2020 | 2529 | 0.16 | Why? |
| Cities | 3 | 2018 | 4937 | 0.15 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.15 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.15 | Why? |
| Poverty | 2 | 2018 | 2302 | 0.15 | Why? |
| Dengue Vaccines | 1 | 2017 | 123 | 0.15 | Why? |
| Interleukins | 1 | 2021 | 762 | 0.15 | Why? |
| Host Specificity | 1 | 2020 | 926 | 0.15 | Why? |
| United States | 6 | 2020 | 46150 | 0.15 | Why? |
| Plasmodium falciparum | 1 | 2019 | 337 | 0.15 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.15 | Why? |
| Population Dynamics | 1 | 2019 | 378 | 0.15 | Why? |
| Culicidae | 1 | 2017 | 239 | 0.15 | Why? |
| Time | 1 | 2018 | 631 | 0.15 | Why? |
| Surveys and Questionnaires | 8 | 2021 | 43792 | 0.14 | Why? |
| Horses | 1 | 2017 | 474 | 0.14 | Why? |
| Yellow Fever | 1 | 2018 | 231 | 0.14 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.14 | Why? |
| Pregnancy Trimester, First | 1 | 2017 | 366 | 0.14 | Why? |
| Social Environment | 1 | 2018 | 389 | 0.14 | Why? |
| Ferrets | 1 | 2020 | 1201 | 0.14 | Why? |
| Urban Health | 1 | 2018 | 382 | 0.14 | Why? |
| Aged | 11 | 2021 | 215776 | 0.14 | Why? |
| Central Nervous System | 1 | 2020 | 701 | 0.14 | Why? |
| Urine | 1 | 2017 | 469 | 0.14 | Why? |
| Developed Countries | 1 | 2018 | 500 | 0.13 | Why? |
| Hospitals, Public | 1 | 2020 | 774 | 0.13 | Why? |
| Retrospective Studies | 9 | 2021 | 105322 | 0.13 | Why? |
| Containment of Biohazards | 1 | 2020 | 762 | 0.13 | Why? |
| Neonatal Screening | 1 | 2017 | 285 | 0.13 | Why? |
| Morbidity | 1 | 2020 | 1426 | 0.13 | Why? |
| Coleoptera | 1 | 2013 | 13 | 0.13 | Why? |
| Altitude | 1 | 2017 | 311 | 0.13 | Why? |
| Air Travel | 1 | 2020 | 585 | 0.13 | Why? |
| Europe | 3 | 2020 | 12702 | 0.13 | Why? |
| India | 2 | 2021 | 11875 | 0.13 | Why? |
| Lymph Nodes | 1 | 2020 | 1060 | 0.13 | Why? |
| Immunity, Herd | 1 | 2021 | 1011 | 0.13 | Why? |
| Communicable Diseases | 2 | 2018 | 2148 | 0.13 | Why? |
| Communicable Disease Control | 6 | 2020 | 29620 | 0.13 | Why? |
| Middle East | 1 | 2018 | 1418 | 0.13 | Why? |
| Climate | 1 | 2018 | 557 | 0.12 | Why? |
| Infant | 4 | 2021 | 30274 | 0.12 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.12 | Why? |
| Child | 5 | 2021 | 70012 | 0.12 | Why? |
| Imaging, Three-Dimensional | 1 | 2018 | 680 | 0.12 | Why? |
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1316 | 0.12 | Why? |
| Communication | 2 | 2021 | 5206 | 0.12 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.12 | Why? |
| Infectious Disease Incubation Period | 1 | 2020 | 1033 | 0.12 | Why? |
| Basic Reproduction Number | 2 | 2021 | 2676 | 0.12 | Why? |
| Publications | 1 | 2017 | 463 | 0.12 | Why? |
| Cohort Studies | 5 | 2018 | 36005 | 0.12 | Why? |
| General Practitioners | 1 | 2019 | 568 | 0.12 | Why? |
| Demography | 1 | 2019 | 1660 | 0.11 | Why? |
| Ships | 1 | 2020 | 1046 | 0.11 | Why? |
| Humidity | 1 | 2018 | 944 | 0.11 | Why? |
| Blister | 1 | 2013 | 119 | 0.11 | Why? |
| Diabetes Mellitus | 1 | 2014 | 8207 | 0.11 | Why? |
| Health Care Costs | 1 | 2020 | 1007 | 0.11 | Why? |
| Hemoglobins | 1 | 2017 | 958 | 0.11 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.11 | Why? |
| Educational Status | 1 | 2018 | 1451 | 0.11 | Why? |
| Biopsy | 1 | 2020 | 2811 | 0.11 | Why? |
| Antitubercular Agents | 1 | 2018 | 775 | 0.11 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.11 | Why? |
| Equipment Contamination | 1 | 2020 | 1308 | 0.11 | Why? |
| Virulence | 1 | 2018 | 2172 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.11 | Why? |
| Autoimmunity | 1 | 2018 | 841 | 0.11 | Why? |
| Odds Ratio | 2 | 2020 | 5861 | 0.11 | Why? |
| Breast Feeding | 2 | 2020 | 1585 | 0.11 | Why? |
| Pulmonary Artery | 1 | 2018 | 803 | 0.11 | Why? |
| Japan | 2 | 2021 | 6653 | 0.11 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.11 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.10 | Why? |
| Macaca mulatta | 1 | 2020 | 3716 | 0.10 | Why? |
| Age Distribution | 1 | 2020 | 3567 | 0.10 | Why? |
| Dermatitis | 1 | 2013 | 188 | 0.10 | Why? |
| Image Interpretation, Computer-Assisted | 1 | 2017 | 665 | 0.10 | Why? |
| Anemia | 1 | 2017 | 789 | 0.10 | Why? |
| Environmental Exposure | 1 | 2021 | 1558 | 0.10 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.10 | Why? |
| United Kingdom | 2 | 2021 | 18046 | 0.10 | Why? |
| Saudi Arabia | 1 | 2021 | 4423 | 0.10 | Why? |
| Measles | 1 | 2017 | 608 | 0.10 | Why? |
| Travel-Related Illness | 1 | 2017 | 1357 | 0.10 | Why? |
| Hand Hygiene | 1 | 2020 | 1493 | 0.10 | Why? |
| Headache | 1 | 2020 | 2257 | 0.10 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.09 | Why? |
| Kidney Diseases | 1 | 2020 | 1434 | 0.09 | Why? |
| Dexamethasone | 1 | 2020 | 2055 | 0.09 | Why? |
| Clinical Protocols | 1 | 2020 | 2734 | 0.09 | Why? |
| Autopsy | 1 | 2020 | 3495 | 0.09 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.09 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.09 | Why? |
| Influenza A virus | 1 | 2020 | 2234 | 0.09 | Why? |
| Software | 1 | 2020 | 2501 | 0.09 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.09 | Why? |
| Myocardium | 1 | 2020 | 2323 | 0.09 | Why? |
| Temperature | 1 | 2018 | 2305 | 0.09 | Why? |
| Diarrhea | 1 | 2020 | 2743 | 0.09 | Why? |
| Masks | 2 | 2021 | 8528 | 0.09 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.09 | Why? |
| Genomics | 1 | 2020 | 3118 | 0.09 | Why? |
| Motivation | 1 | 2018 | 1640 | 0.08 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Drug Therapy, Combination | 1 | 2021 | 7268 | 0.08 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.08 | Why? |
| Homeless Persons | 1 | 2018 | 1171 | 0.08 | Why? |
| Blood Donors | 1 | 2020 | 2956 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Models, Statistical | 3 | 2020 | 5312 | 0.08 | Why? |
| Placenta | 1 | 2016 | 1531 | 0.08 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.08 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.08 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2019 | 2955 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.07 | Why? |
| Politics | 1 | 2019 | 1824 | 0.07 | Why? |
| Risk | 1 | 2017 | 5288 | 0.07 | Why? |
| Occupational Exposure | 2 | 2020 | 4742 | 0.07 | Why? |
| Spain | 2 | 2020 | 15545 | 0.07 | Why? |
| China | 3 | 2020 | 50654 | 0.07 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 11367 | 0.07 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.07 | Why? |
| Virus Shedding | 1 | 2020 | 5834 | 0.07 | Why? |
| Australia | 1 | 2017 | 6306 | 0.07 | Why? |
| Health Services Needs and Demand | 1 | 2018 | 3419 | 0.06 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.06 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.06 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.06 | Why? |
| Patient Acceptance of Health Care | 2 | 2021 | 5002 | 0.06 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.06 | Why? |
| Leukotrienes | 1 | 2021 | 37 | 0.06 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.06 | Why? |
| Arachidonic Acid | 1 | 2021 | 90 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Immunocompromised Host | 1 | 2018 | 5150 | 0.05 | Why? |
| Breast Milk Expression | 1 | 2020 | 49 | 0.05 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.05 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.05 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.05 | Why? |
| Animal Husbandry | 1 | 2020 | 162 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Internship and Residency | 1 | 2020 | 4987 | 0.05 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.05 | Why? |
| Poultry | 1 | 2020 | 437 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2021 | 10083 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Italy | 2 | 2020 | 38444 | 0.05 | Why? |
| Heart Failure | 1 | 2020 | 6638 | 0.05 | Why? |
| Hypertension | 1 | 2020 | 8895 | 0.05 | Why? |
| Airports | 1 | 2020 | 284 | 0.04 | Why? |
| Cuba | 1 | 2018 | 202 | 0.04 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.04 | Why? |
| Students | 1 | 2015 | 5255 | 0.04 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.04 | Why? |
| Acyclovir | 1 | 2017 | 154 | 0.04 | Why? |
| Pets | 1 | 2020 | 314 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Mink | 1 | 2020 | 399 | 0.04 | Why? |
| Critical Illness | 2 | 2020 | 17281 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Aircraft | 1 | 2020 | 498 | 0.04 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.04 | Why? |
| Yellow Fever Vaccine | 1 | 2018 | 198 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Quarantine | 2 | 2020 | 18418 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| North America | 1 | 2020 | 1400 | 0.04 | Why? |
| Bias | 1 | 2021 | 1109 | 0.04 | Why? |
| Birds | 1 | 2018 | 412 | 0.04 | Why? |
| Prospective Studies | 1 | 2020 | 43301 | 0.04 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.04 | Why? |
| Th1 Cells | 1 | 2021 | 1228 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2017 | 260 | 0.03 | Why? |
| Measles Vaccine | 1 | 2017 | 301 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2021 | 1887 | 0.03 | Why? |
| Orthomyxoviridae Infections | 1 | 2020 | 1001 | 0.03 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Vaccination Refusal | 1 | 2021 | 831 | 0.03 | Why? |
| Bangladesh | 1 | 2018 | 1620 | 0.03 | Why? |
| Intention | 1 | 2021 | 1380 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Anxiety | 1 | 2017 | 17311 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Netherlands | 1 | 2020 | 3533 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.03 | Why? |
| Ivermectin | 1 | 2020 | 973 | 0.03 | Why? |
| Enzyme Inhibitors | 1 | 2021 | 1881 | 0.03 | Why? |
| Feasibility Studies | 1 | 2020 | 3467 | 0.03 | Why? |
| Patient Participation | 1 | 2017 | 829 | 0.02 | Why? |
| Perception | 1 | 2021 | 2827 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2019 | 5440 | 0.02 | Why? |
| Health Surveys | 1 | 2019 | 2841 | 0.02 | Why? |
| Mothers | 1 | 2018 | 1624 | 0.02 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| Antifungal Agents | 1 | 2017 | 1828 | 0.02 | Why? |
| Renal Insufficiency, Chronic | 1 | 2020 | 2654 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2018 | 3444 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.02 | Why? |
| Immunization, Passive | 1 | 2020 | 10067 | 0.02 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.02 | Why? |
| Brain | 1 | 2020 | 5133 | 0.02 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.01 | Why? |